| Time |
Topic |
|
09:00-09:10
|
Welcome Remarks |
|
|
09:10-10:35
|
Session I: Hormone Receptor-Positive and HER2-Negative Breast Cancer |
한원식(서울대병원) |
|
09:10-09:35
|
Adjuvant CDK4/6 inhibitors and PARP inhibitors |
이장희(이대목동병원) |
|
09:35-10:00
|
Current landscape of precision medicine for HR+ breast cancer |
김지형(강남세브란스병원) |
|
10:00-10:25
|
Antibody-drug conjugates after endocrine treatments in advanced breast cancer
|
이인희(경북대병원) |
| 10:25-10:35
|
Discussion
|
|
|
10:35-10:50
|
Coffee Break
|
|
10:50-12:15
|
Session II: HER2-Positive Breast Cancer |
이근석(국립암센터) |
|
10:50-11:15
|
Optimized approach to triple-positive breast cancer |
배숭준(강남세브란스병원) |
|
11:15-11:40
|
Tailoring HER2-targeted therapy in HER2-positive breast cancer
|
원혜성(의정부성모병원) |
|
11:40-12:05
|
Updated management of brain metastasis in HER2+ |
신정훈(삼성서울병원) |
|
12:05-12:15
|
Discussion |
|
|
12:15-13:20
|
Lunch |
|
13:20-14:45
|
Session III: Triple-Negative Breast Cancer |
박인혜(고대구로병원) |
|
13:20-13:45
|
Systemic treatment of ER-low or HER2-low breast cancer |
이지은(서울성모병원) |
|
13:45-14:10
|
Immunotherapy and adverse effects in TNBC
|
채희정(분당서울대병원) |
|
14:10-14:35
|
Antibody-drug conjugates in early and metastatic TNBC |
홍지형(국립암센터) |
|
14:35-14:45
|
Discussion |
|
14:45-15:00
|
Coffee Break |
|
15:00-16:25
|
Session IV: Treatment Strategies for Special Population |
강태우(부산대병원) |
|
15:00-15:25
|
Innovative approach for invasive lobular cancer |
김은영(강북삼성병원) |
|
15:25-15:50
|
Risk-adaptive treatment for elderly patients |
선우영(대전성모병원) |
|
15:50-16:15
|
Mind adverse effects of novel targeted agents (ADC, CDK4/6i, etc) |
김민환(연세암병원) |
|
16:15-16:25
|
Discussion |
|
|
16:25-16:35
|
Closing Remarks |
